EDISTRIDE

This brand name is authorized in Austria, Estonia, Spain, Croatia, Ireland, Lithuania, Poland

Active ingredients

The drug EDISTRIDE contains one active pharmaceutical ingredient (API):

1 Dapagliflozin propanediol monohydrate UNII 1ULL0QJ8UC - DAPAGLIFLOZIN

Dapagliflozin is a highly potent, selective and reversible inhibitor of SGLT2. SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Dapagliflozin improves both fasting and post-prandial plasma glucose levels by reducing renal glucose reabsorption leading to urinary glucose excretion. Read about Dapagliflozin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A10BK01	Dapagliflozin	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Discover more medicines within A10BK01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1702875, 1702886, 1702897, 1702909, 1702910, 1702921, 1702932, 1702943, 1702954, 1702965
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1151052007
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1078660, 1078661, 1078662, 1078663, 1078664, 1078665, 1078666, 1078667, 1078668, 1078669
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100359057, 100359063